查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1378847

製藥市場：2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測

Pharmerging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

概要

2022年全球醫藥市場規模達11億美元。展望未來， IMARC Group預計到2028年市場規模將達到22億美元，2022-2028年複合年成長率（CAGR）為12.2%。

醫藥併購是指在醫藥市場中地位較低但成長較快的一群國家。一些主要的醫藥市場包括中國、印度、巴西、俄羅斯、南非、墨西哥、印尼、土耳其等。

醫療保健支出的增加以及私立醫院數量的增加目前正在推動全球醫藥市場的成長。此外，多種慢性病的高盛行率以及消費者對早期疾病檢測和治療程序的意識不斷增強，進一步促進了市場的成長。此外，老年人口的增加也增加了對藥品的需求，他們更容易罹患嚴重的疾病，如失智症、高血壓、心臟衰竭等。此外，各國為降低慢性病治療成本而推出的政府政策和報銷計畫也推動了市場的成長。此外，製藥國家越來越多的保險公司提供多種保單以減少自付費用，這進一步增加了這些國家的藥品需求。除此之外，生物技術、免疫學、腫瘤學等領域廣泛研發活動的投資不斷增加，以引進先進的治療方法，也促進了市場的成長。

本報告回答的關鍵問題：

  • 迄今為止，全球製藥市場的表現如何，未來幾年將如何表現？
  • 主要區域市場有哪些？
  • COVID-19 對全球醫藥市場有何影響？
  • 基於產品的市場區隔是什麼？
  • 根據指示，市場的細分是什麼？
  • 基於配銷通路的市場區隔是什麼？
  • 產業價值鏈的各個階段是什麼？
  • 市場的關鍵促進因素和挑戰是什麼？
  • 全球醫藥市場的結構如何？誰是主要參與者？
  • 市場競爭程度如何？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球醫藥市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：按產品分類的市場區隔

  • 製藥
    • 市場走向
    • 主要類型
      • 專利處方藥
      • 非專利處方藥
      • 非處方藥
    • 市場預測
  • 衛生保健
    • 市場走向
    • 主要類型
      • 醫療設備
      • 臨床診斷
      • 其他
    • 市場預測

第 7 章：按跡象分類的市場

  • 生活方式疾病
    • 市場走向
    • 市場預測
  • 癌症與自體免疫疾病
    • 市場走向
    • 市場預測
  • 傳染性疾病
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：按配銷通路分類的市場區隔

  • 醫院
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 網路商店
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：按國家/地區分類的市場細分

  • 第一級
    • 中國
      • 市場走向
      • 市場預測
  • 第二級
    • 印度
      • 市場走向
      • 市場預測
    • 巴西
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 南非
      • 市場走向
      • 市場預測
  • 第三級
    • 阿根廷
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 波蘭
      • 市場走向
      • 市場預測
    • 烏克蘭
      • 市場走向
      • 市場預測
    • 土耳其
      • 市場走向
      • 市場預測
    • 沙烏地阿拉伯
      • 市場走向
      • 市場預測
    • 埃及
      • 市場走向
      • 市場預測
    • 阿爾及利亞
      • 市場走向
      • 市場預測
    • 奈及利亞
      • 市場走向
      • 市場預測
    • 泰國
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 巴基斯坦
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Sanofi SA
    • Pfizer Inc.
    • AstraZeneca Plc.
    • GlaxoSmithKline Plc.
    • F. Hoffmann-La Roche AG (Roche AG)
    • Eli Lilly and Company
    • Johnson & Johnson
    • Abbott Laboratories
    • Novartis AG
    • Teva Pharmaceutical Limited
Product Code: SR112023A3441

Abstract

The global pharmerging market size reached US$ 1.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.2 Billion by 2028, exhibiting a growth rate (CAGR) of 12.2% during 2022-2028.

Pharmerging refers to a group of countries that hold low positioning in the pharmaceutical market but have a speedy growth. Some of the key pharmerging markets include China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, etc.

The increasing healthcare expenditures along with the rising number of private hospitals are currently propelling the global pharmerging market growth. Additionally, the high prevalence of numerous chronic diseases and growing consumer awareness towards early disease detection and treatment procedures are further augmenting the market growth. Moreover, the increasing geriatric population, who are more prone to serious medical conditions, such as dementia, hypertension, cardiac failure, etc., is also bolstering the demand for pharmaceuticals. Additionally, the introduction of government policies and reimbursement schemes across various countries for reducing the cost of treatment for chronic diseases is also propelling the market growth. Moreover, the growing number of insurance companies in the pharmerging countries offering numerous insurance policies to decrease the out-of-the-pocket expenditures is further augmenting the demand of pharmaceuticals in these countries. Apart from this, the rising investments in extensive R&D activities in the fields of biotechnology, immunology, oncology, etc., for the introduction of advanced treatments are also catalyzing the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmerging market report, along with forecasts at the global and country level from 2023-2028. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

Pharmaceuticals

Patented Prescription Drugs

Generic Prescription Drugs

OTC Drugs

Healthcare

Medical Devices

Clinical Diagnosis

Others

Breakup by Indication:

Lifestyle Diseases

Cancer and Autoimmune Diseases

Infectious Diseases

Others

Breakup by Distribution Channel:

Hospitals

Retail Pharmacies

Online Stores

Others

Breakup by Country:

Tier I

China

Tier II

India

Brazil

Russia

South Africa

Tier III

Argentina

Mexico

Poland

Ukraine

Turkey

Saudi Arabia

Egypt

Algeria

Nigeria

Thailand

Indonesia

Pakistan

Others

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited.

Key Questions Answered in This Report:

  • How has the global pharmerging market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What is the impact of COVID-19 on the global pharmerging market?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the market?
  • What is the structure of the global pharmerging market and who are the key players?
  • What is the degree of competition in the market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmerging Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Pharmaceutical
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Patented Prescription Drugs
      • 6.1.2.2 Generic Prescription Drugs
      • 6.1.2.3 OTC Drugs
    • 6.1.3 Market Forecast
  • 6.2 Healthcare
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Medical Devices
      • 6.2.2.2 Clinical Diagnosis
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Indication

  • 7.1 Lifestyle Diseases
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cancer and Autoimmune Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Country

  • 9.1 Tier I
    • 9.1.1 China
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
  • 9.2 Tier II
    • 9.2.1 India
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Brazil
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 Russia
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Africa
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
  • 9.3 Tier III
    • 9.3.1 Argentina
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 Mexico
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 Poland
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Ukraine
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Turkey
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Saudi Arabia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Egypt
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
    • 9.3.8 Algeria
      • 9.3.8.1 Market Trends
      • 9.3.8.2 Market Forecast
    • 9.3.9 Nigeria
      • 9.3.9.1 Market Trends
      • 9.3.9.2 Market Forecast
    • 9.3.10 Thailand
      • 9.3.10.1 Market Trends
      • 9.3.10.2 Market Forecast
    • 9.3.11 Indonesia
      • 9.3.11.1 Market Trends
      • 9.3.11.2 Market Forecast
    • 9.3.12 Pakistan
      • 9.3.12.1 Market Trends
      • 9.3.12.2 Market Forecast
    • 9.3.13 Others
      • 9.3.13.1 Market Trends
      • 9.3.13.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Sanofi S.A.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Pfizer Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 AstraZeneca Plc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 GlaxoSmithKline Plc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG (Roche AG)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Johnson & Johnson
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Abbott Laboratories
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Novartis AG
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Teva Pharmaceutical Limited
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financial
      • 13.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pharmerging Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmerging Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Pharmerging Market: Breakup by Product (in %), 2022
  • Figure 4: Global: Pharmerging Market: Breakup by Indication (in %), 2022
  • Figure 5: Global: Pharmerging Market: Breakup by Distribution Channel (in %), 2022
  • Figure 6: Global: Pharmerging Market: Breakup by Country (in %), 2022
  • Figure 7: Global: Pharmerging Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 8: Global: Pharmerging (Pharmaceuticals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Pharmerging (Pharmaceuticals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Pharmerging (Healthcare) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Pharmerging (Healthcare) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Pharmerging (Lifestyle Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Pharmerging (Lifestyle Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Pharmerging (Cancer and Autoimmune Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Pharmerging (Cancer and Autoimmune Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Pharmerging (Infectious Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Pharmerging (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Pharmerging (Other Indications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Pharmerging (Other Indications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Pharmerging (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Pharmerging (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Pharmerging (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Pharmerging (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Pharmerging (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Pharmerging (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Pharmerging (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Pharmerging (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Tier I: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Tier I: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: China: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: China: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Tier II: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Tier II: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: India: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: India: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Brazil: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Brazil: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Russia: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Russia: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: South Africa: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: South Africa: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Tier III: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Tier III: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Argentina: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Argentina: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Mexico: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Mexico: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Poland: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Poland: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Ukraine: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Ukraine: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Turkey: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Turkey: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Saudi Arabia: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Saudi Arabia: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Egypt: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Egypt: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Algeria: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Algeria: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Nigeria: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Nigeria: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Thailand: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Thailand: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Indonesia: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Indonesia: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Pakistan: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Pakistan: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Others: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Others: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Global: Pharmerging Industry: SWOT Analysis
  • Figure 71: Global: Pharmerging Industry: Value Chain Analysis
  • Figure 72: Global: Pharmerging Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmerging Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Pharmerging Market Forecast: Breakup by Product (in Million US$), 2023-2028
  • Table 3: Global: Pharmerging Market Forecast: Breakup by Indication (in Million US$), 2023-2028
  • Table 4: Global: Pharmerging Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Pharmerging Market Forecast: Breakup by Country (in Million US$), 2023-2028
  • Table 6: Global: Pharmerging Market: Competitive Structure
  • Table 7: Global: Pharmerging Market: Key Players